Pharmaceutical Market in Turmoil: Breakthroughs and Disappointments Amid COVID-19 Pandemic

Strategic Insights -

The COVID-19 pandemic has sent shockwaves through the pharmaceutical market, overshadowing wider trends and challenges facing industry leaders. Despite the unprecedented speed of vaccine development, major manufacturers like Pfizer and AstraZeneca, the US pharmaceutical market has seen mixed results this fall, with breakthroughs and disappointments for top manufacturers like Gilead Sciences and Eli Lilly.

Key Takeaways:

  • Gilead Sciences faces challenges to its dominance in the HIV PrEP market due to a study showing an HIV PrEP vaccine being more effective in preventing HIV infection in women than Truvada.
  • Gilead has reported $873 million in revenue from the sale of remdesivir as an emergency COVID-19 therapeutic, making it a top-selling drug for the company this year.
  • Eli Lilly's COVID-19 antibody therapy received emergency use authorization from the FDA, but its third-quarter profit expectations were missed, and its diabetes drug Trulicity faced softer sales.
  • Biogen's Alzheimer's drug aducanumab was rejected by the FDA due to unconvincing evidence of its effectiveness, causing a 28% drop in share prices.
  • Drug prices remain high for many patients, despite weak sales, inviting regulation and scrutiny from consumer advocacy groups.

Statistics:

  • Gilead Sciences reported $873 million in revenue from the sale of remdesivir in the last reported month.
  • Eli Lilly's third-quarter profit expectations were missed, with a 28% drop in share prices following the rejection of Biogen's Alzheimer's drug aducanumab.
  • The FDA approved emergency use authorization for Eli Lilly's COVID-19 antibody therapy this month.
  • 28% drop in Biogen's share prices following the rejection of aducanumab.
  • Medicare beneficiaries' potential benefit from the Lower Drug Cost Act, which would enable Medicare to negotiate prices for beneficiaries.

Sources:

  • Pfizer and AstraZeneca, major manufacturers researching COVID-19 vaccines.
  • Gilead Sciences, manufacturer of Truvada and Descovy.
  • Eli Lilly, developer of COVID-19 antibody therapy.
  • Biogen, manufacturer of Alzheimer's drug aducanumab.
  • Rep. Elijah Cummings' Lower Drug Cost Now Act.
  • Fitch Ratings, forecasting the likelihood of the Lower Drug Cost Act passing under a Biden administration.
  • CVS Health, pharmacy benefit manager.
  • Cigna, pharmacy benefit manager.
  • Madison Business Review.